$13.40
-0.17-1.25%
Ult. Agg.: Oct 23, 4:51 PM
Syndax Pharmaceuticals (SNDX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.46 | $-0.59 | $-0.60 | $-0.72 |
| Actual | $-0.55 | $-0.48 | $-0.78 | $-0.70 |
| Surprise | -19.6% | +18.6% | -30.0% | +2.78% |
| Revenue | ||||
| Estimate | $79.9M | $69.9M | $63.3M | $48.3M |
| Actual | $72.8M | $64.9M | $68.7M | $45.9M |
| Surprise | -8.85% | -7.15% | +8.55% | -4.95% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.49 | $-0.46 | $-0.64 | $-0.55 |
| Revenue | ||||
| Consensus | $81.8M | $95.0M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $-0.55 | $-0.46 | -19.6 % |
| Q1 | Apr 30, 2026 | $-0.48 | $-0.59 | 18.6 % |
| Q4 | Feb 26, 2026 | $-0.78 | $-0.60 | -30.0 % |
| Q3 | Nov 3, 2025 | $-0.70 | $-0.72 | 2.78 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $72.79M | $79.86M | -8.85 % |
| Q1 | Apr 30, 2026 | $64.86M | $69.86M | -7.15 % |
| Q4 | Feb 26, 2026 | $68.73M | $63.31M | 8.55 % |
| Q3 | Nov 3, 2025 | $45.87M | $48.26M | -4.95 % |